GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Iran Daru (XTEH:IRDR1) » Definitions » Return-on-Tangible-Equity

Iran Daru (XTEH:IRDR1) Return-on-Tangible-Equity : 0.00% (As of . 20)


View and export this data going back to 1990. Start your Free Trial

What is Iran Daru Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Iran Daru's annualized net income for the quarter that ended in . 20 was IRR Mil. Iran Daru's average shareholder tangible equity for the quarter that ended in . 20 was IRR Mil. Therefore, Iran Daru's annualized Return-on-Tangible-Equity for the quarter that ended in . 20 was %.

The historical rank and industry rank for Iran Daru's Return-on-Tangible-Equity or its related term are showing as below:

XTEH:IRDR1's Return-on-Tangible-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.265
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Iran Daru Return-on-Tangible-Equity Historical Data

The historical data trend for Iran Daru's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iran Daru Return-on-Tangible-Equity Chart

Iran Daru Annual Data
Trend
Return-on-Tangible-Equity

Iran Daru Semi-Annual Data
Return-on-Tangible-Equity

Competitive Comparison of Iran Daru's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Iran Daru's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iran Daru's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Iran Daru's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Iran Daru's Return-on-Tangible-Equity falls into.



Iran Daru Return-on-Tangible-Equity Calculation

Iran Daru's annualized Return-on-Tangible-Equity for the fiscal year that ended in . 20 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=/( (+ )/ )
=/
= %

Iran Daru's annualized Return-on-Tangible-Equity for the quarter that ended in . 20 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=/( (+)/ )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is one times the annual (. 20) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Iran Daru  (XTEH:IRDR1) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Iran Daru Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Iran Daru's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Iran Daru (XTEH:IRDR1) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Ayatollah Saeedi Highway, End Of Kermani Street, Moallem Boulevard, Tehran, IRN, 1371658111
Iran Daru is a pharmaceutical company based in Iran. It manufactures and sells pharmaceutical products for antibiotics, cardiovascular agents, and local anesthetic agents. The company manufactures products in three main dosage form categories namely solid, semi-solid, and liquid including tablets, capsules, pellets, sachets, gels, creams, ointments (sterile and non-sterile), spray solutions, and syrups. Products offered by Iran Daru include Diclofenac Potassium, Biotin 5 mg, Tetracycline, Folic acid, Meloxicam, Acetaminophen and Caffeine, and Levocetirizine dihydrochloride, among others. It also exports its products to other countries.

Iran Daru (XTEH:IRDR1) Headlines

No Headlines